AlphAIAlphAI — Financial news for AI agents
news.medtronic.comOCT 72 min read$MDT

Medtronic Announces Final Exchange Ratio of 4.5939 in Split-Off of MiniMed Group, Inc.

Medtronic (MDT) announced a final exchange ratio of 4.5939 shares of MiniMed (MMED) for each Medtronic share in its split-off offer. Up to 225.4 million MiniMed shares will be exchanged, with proration if oversubscribed. The offer expires October 9, 2026, unless extended.

Original reporting
news.medtronic.com
Published Oct 7, 2026, 9:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 9:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Medtronic Announces Final Exchange Ratio of 4.5939 in Split-Off of MiniMed Group, Inc. — source image
Source · news.medtronic.com
Decision brief

The 30-second read

$MDTNeutralHigh
01

Why it matters

The final ratio finalizes the terms of the transaction, enabling investors to assess dilution and valuation impacts ahead of the offer deadline.

02

Market read

First disclosure of the exchange ratio provides actionable information for traders to position before the Oct 9 deadline.

03

What to watch

Regulatory approval timeline and tax treatment of the split‑off could affect the ultimate value to shareholders.

Relevance 8/10Novelty 8/10Timing: before exchange‑offer deadline on Oct 9 2026

Background

Medtronic is executing a split‑off of its MiniMed insulin‑pump business, offering Medtronic shareholders a fixed exchange ratio.

Company-level read

Ticker impact

$MDTNeutralHigh confidence
Context

Medtronic announced the final exchange ratio of 4.5939 for its split‑off of MiniMed, setting the terms of the share‑exchange offer.

Expected impact

potential pressure on Medtronic as shares are exchanged, while MiniMed may see upside as it becomes independent.

Evidence & confidence

First disclosure of the final ratio; market will price the relative value and dilution effects immediately.

$MMEDNeutralHigh confidence
Context

MiniMed Group received the final exchange ratio from Medtronic, determining the number of MiniMed shares to be issued to Medtronic shareholders.

Expected impact

likely upside as investors assess MiniMed's standalone prospects and the exchange ratio.

Evidence & confidence

The ratio sets the conversion terms; investors will evaluate MiniMed's valuation post‑separation.

Market effects

Sector

Healthcare device sector may see re‑rating of Medtronic's exposure to insulin‑pump business.

Regional

U.S. and European markets may adjust Medtronic and MiniMed valuations ahead of the deadline.

Global

Limited to Medtronic and MiniMed; no broad macro impact.

Counterpoint

What could challenge this read

If the exchange ratio undervalues MiniMed, shareholders might reject the offer, pressuring Medtronic shares lower.

Key entities

  • Company
    Medtronic plc

    Global medical technology firm executing the split‑off.

  • Company
    MiniMed Group, Inc.

    Insulin‑pump business being separated from Medtronic.

Read at source← All news

StoryMedtronic Reports Oversubscribed MiniMed Split-Off and Preliminary Proration

Also covered by

6 outlets

Related articles

OCT 23
$MDTMed

Diabetes Dialogue: MiniMed Vivera Data and Twiist Type 2 Clearance

Medtronic's MiniMed Vivera algorithm showed promise in managing type 1 diabetes without meal announcements, with participants maintaining glycemic targets. The twiist AID system from Sequel Med Tech received FDA clearance for type 2 diabetes, showing improved HbA1c and time-in-range in trials. Both systems aim to reduce user input in automated insulin delivery.

hcplive.com2 min
OCT 23
$MDTMed

Medtronic reports real-world findings for cardiac ablation systems

Medtronic reported positive real-world registry findings for its cardiac ablation technologies, presented at the APHRS 2026 meeting. The PulseSelect PFA system showed a 100% success rate in AFib patients with a 0.09% complication rate. The Affera system with Sphere-9 catheter had a 1.1% major complication rate in AFib patients and an 87% success rate in VT patients. Medtronic's vice-president expressed confidence in the safety and performance of these technologies.

finance.yahoo.com2 min
OCT 22
$JNJMedAI 9/10

J&J, Medtronic present pulsed field ablation data from global real-world use

J&J and Medtronic presented data on their pulsed field ablation platforms at the Asia Pacific Heart Rhythm Society meeting. J&J's Varipulse Pro showed 100% procedural success in 225 European patients with no major complications. Medtronic's PulseSelect had a 100% success rate and 0.09% major complication rate in 1,160 global patients. Both companies also shared data on upcoming systems and catheters.

massdevice.com2 min
OCT 20
MedAI 8/10

Medtronic’s next-gen pacemaker portfolio secures CE mark

Medtronic's Vitalis portfolio of next-gen pacemakers, designed for conduction system pacing (CSP) therapy, received a CE mark. The five pacemakers include advanced features like AdaptivCSP for heart synchrony. Medtronic claims this offers a more physiologic pacing option. GlobalData reports Medtronic leads the US pacemaker market with 58.7% share in 2025, with the global market growing at a 4.9% CAGR.

medicaldevice-network.com2 min
OCT 19
$MDTHigh

Medtronic nets CE Mark for Vitalis family of conduction system pacemakers

Medtronic (MDT) received CE Mark approval for its Vitalis family of pacemakers, designed for conduction system pacing. The portfolio includes five devices targeting various patient needs, such as the ReSyncra CSP for cardiac resynchronization therapy. The devices aim to improve heart synchronization by targeting conductive tissues, offering personalized therapy and remote monitoring. According to Medtronic, the portfolio builds on its history in cardiac electrophysiology therapies.

massdevice.com2 min